Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Harmony Biosciences Holdings, Inc. logoHarmony Biosciences Holdings, Inc.

HRMY · Nasdaq · USD · Market cap $1.9B · 293 employees

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.

FAIL · Does not pass the screen
32.59 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price32.59 USD at the 20 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 20 Nov 2026
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 1.09)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $61.88 to $66.22, base estimate $61.88 (screen dated 2026-11-20).

Current read
Distribution ?
Undervalued · screened 2026-11-20
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 1.09, read 2026-11-19
  • Ethical does not pass the values gate
Price32.59 USD
Fair value61.88
Ethical score70.0/100
Value readUndervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-11-11Read Distribution33.55-2.9% to today ✓Markdown gives way to Distribution after a 15% slide in 4 weeks
2026-10-11Read Markdown39.36-17.2% to today ✓Accumulation gives way to Markdown first Markdown read since July
2026-09-01Read Accumulation39.87-18.3% to today Markup gives way to Accumulation after an 18% rise in 4 weeks
2026-08-01Read Markup33.77-3.5% to today Markdown gives way to Markup

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Harmony Biosciences Holdings, Inc. holds its Distribution at $32.59. Consolidating, no directional conviction, held for 9 days.

As held on the ledger · 2026-11-20
PhaseDistribution · caution
Quantitative stateConsolidating, no directional conviction, held for 9 days
Price at the screen$32.59
Valuation10.93 trailing · 5.44 forward price to earnings
Values screenFAIL · score 70.0
Beta0.98
The Workings

Five Screens: HRMY's Results

FAIL. Accounts receivable

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 12.87% Below 33% Pass
Interest-bearing cash 8.42% Below 33% Pass
Receivables 66.79% Below 49% Fail
Revenue purity 2.52% Below 5% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Harmony Biosciences Holdings,'s business is fine, but its receivables are about 67% of its assets, well over the ~49% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when HRMY's ethical verdict changes

Today HRMY does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 47% discount to our $61.88 fair value, 12.30% revenue growth.

Method.

61.88Conservative61.88Base case66.22Growth case 32.59Price

USD, 2026-11-20 screen. A 47.3% under base.

The Street's Range
32.00Street low 49.50Street average 70.00Street high 32.59Price

Street: 12 covering, consensus Buy. Average target +52%.

Chart
The Business, in Plain Words

Rare Disease Drugmaker Trades At A Steep Discount

A patient with narcolepsy who finally sleeps through the night thanks to one approved pill shows how focused biotechs can turn rare conditions into steady revenue. Harmony Biosciences already sells WAKIX at a 17 percent revenue growth rate, delivers 16 percent profit margins and posts 18 percent return on equity, all while clearing our ethical screen without issue. The forward price to earnings ratio of just 5.6 times leaves plenty of room before it matches the 43 dollar analyst median target.

Yet the moat remains unknown and the business sits in a sector where one regulatory setback or fresh competitor can erase years of progress. That combination explains the none rating despite the 59 percent gap between the current 33.77 dollar price and our fair value estimate. High volatility around single-product exposure keeps the overall risk elevated.

Analysis, not advice.

The fundamentals · plain-English read
Forward P/E5.4xcheap for a company growing this fast
Trailing P/E10.9xreasonably valued
EPS, trailing3.02
EPS, forward6.06
Revenue growth+12.3%steady growth
Profit margin18.1%healthy profit margins
Return on equity18.7%a solid return on shareholder capital
FCF yield9.89%
Debt to equity0.14minimal debt: a conservative balance sheet
Current ratio3.44comfortably covers its short-term bills
Beta0.98steadier than the market
Short interest, float0.15%
52-week range25.90 - 43.49
Market cap$1.9B
Employees293

HRMY-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Distribution $33.11 +0.3% Entry 20
2026-11-18 Distribution $33.01 -1.6% Entry 19
2026-11-11 Distribution · changed $33.55 -9.4% Entry 18

The framework has shifted from markdown to distribution since the last review.

2026-11-04 Markdown $37.02 -2.3% Entry 17
2026-11-03 Markdown $37.91 -2.2% Entry 16
2026-11-02 Markdown $38.76 +0.0% Entry 15
2026-11-01 Markdown $38.76 +7.3% Entry 14
2026-10-31 Markdown $36.13 +0.0% Entry 13
2026-10-30 Markdown $36.13 +0.0% Entry 12
2026-10-29 Markdown $36.13 -5.7% Entry 11

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on HRMY

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in HRMY's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · HRMY
DateInsiderTitleTypeSharesValue
2026-09-16 Budur Kumar CHIEF MEDICAL OFFICER S - Sale+OE 38,452 $1,655,416

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $30.18 +18.5% · $1,185 +18.5%
2 months $28.89 +23.8% · $1,238 +23.8%
3 months $27.79 +28.7% · $1,287 +28.7%
6 months $39.59 -9.7% · $904 -9.7%
1 year $35.85 -0.2% · $998 -0.2%
2 years $29.92 +19.6% · $1,196 +19.6%
3 years $34.95 +2.4% · $1,024 +2.4%
5 years $31.99 +11.8% · $1,118 +11.8%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever HRMY does next, these words stay.

Harmony Biosciences Holdings, Inc. · HRMY · Distribution · $32.59
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.